ArticleCureus2025
Autoimmune Hemolytic Anemia as an Initial Manifestation of Splenic Marginal Zone Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Classic Hairy Cell Leukemia and Related Disorders: An Updated Review of Molecular Features and Personalized Therapies.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune hemolytic anemia (AIHA) is caused by autoantibodies that target and destroy the individual's own red blood cells (RBCs). Warm AIHA is due to antibodies that are active at body temperature and are the most common type of AIHA. Herein, we report a 49-year-old woman who presented with breathlessness, easy fatiguability, and palpitations with blood picture showing severe anemia requiring multiple blood transfusions, leucocytosis, Direct Coombs Test (DCT) positivity, and elevated lactate dehydrogenase (LDH). The patient later developed increasing leukocytosis, for which bone marrow biopsy and immunophenotyping using flow cytometry were done, confirming the presence of underlying splenic marginal zone lymphoma resulting in secondary AIHA. The patient was referred to the hematology department and was started on treatment with steroids and rituximab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.